Primary Cardiac Angiosarcoma with Good Response to Paclitaxel

Prabu, M.; Thulkar, Sanjay; Ray, Ruma; Bakhshi, Sameer

doi:10.1097/jto.0b013e31822e2973

Cited by 16 publications

(13 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This work was funded in part by the Robert Bosch Foundation [1) clinical research grant for CMR risk stratification in HCM, and 2) clinical research grant for inflammatory heart disease KKF-11-18].…”

Section: Sources Of Fundingmentioning

confidence: 99%

Favorable Course of Pericardial Angiosarcoma Under Paclitaxel Followed by Pazopanib Treatment Documented by Cardiovascular Magnetic Resonance Imaging

Ong

Greulich²,

Schumm³

et al. 2012

Circulation

View full text Add to dashboard Cite

A 31-year-old white male patient was transferred from a local district hospital for suspected pericardial mass. Two months earlier he had been admitted there for worsening shortness of breath and subsequently was diagnosed with a large pericardial effusion. He had no other pertinent past medical history. After pericardiocentesis (1.5 L) there was no evidence of malignant cells on cytology, and a computed tomography scan did not reveal any abnormality. Thus, the incident was interpreted as (viral) infectious pericarditis and the patient clinically improved under anti-inflammatory medication within 4 weeks. After that, while on a holiday in Tunisia, he again reported worsening shortness of breath. On day 6 of his holiday, he suddenly passed out and was admitted to a local hospital for unexplained syncope, where again a large pericardial effusion was seen. This time, after another pericardiocentesis (1 L), a pericardial mass was suspected by echocardiography and the patient was transferred back to Germany for further workup.Cardiovascular magnetic resonance on the day of admission to our center revealed a large inhomogeneous mass within the pericardium and the mediastinal space infiltrating the big vessels, as well as the right atrium (Figure 1 and online-only Data Supplement Movies I and II). The mass severely compressed the entire heart, leading to hemodynamic compromise. Therefore, in our multidisciplinary oncology conference, the decision for urgent surgical sampling for

show abstract

Section: Sources Of Fundingmentioning

confidence: 99%

Favorable Course of Pericardial Angiosarcoma Under Paclitaxel Followed by Pazopanib Treatment Documented by Cardiovascular Magnetic Resonance Imaging

Ong

Greulich²,

Schumm³

et al. 2012

Circulation

View full text Add to dashboard Cite

show abstract

“…There are insufficient data about the role of adjuvant chemotherapy. Chemotherapy regimens containing doxorubicin, ifosphamide, cisplatin and paclitaxel have been tried (6,12,13,14). For advanced disease doxorubicin and weekly paclitaxel seem to provide some improvement in progression free survival (14).…”

Section: Discussionmentioning

confidence: 99%

Primary Cardiac Angiosarcoma: A Case Report

Durnalı¹,

Yüksel²,

Altundag³

et al. 2015

Acta Oncol Tur.

View full text Add to dashboard Cite

ÖZETPrimer kardiyak anjiosarkoma, kötü prognozlu nadir bir hastalıktır. Açık kardiyak cerrahi operasyon olan ve sağ atriumda kardiyak anjiosarkoma tanısı alan 34 yaşında erkek hasta tıbbi onkoloji bölümüne başvurdu. Tümörün tam küratif rezeksiyonu mümkün olmamıştı ve hastaya postoperatif dönemde 6 siklus kombinasyon kemoterapi rejimi (doksorubisin ve mesna korumasıyla ifosfamid) verildi. Hastada 8 ay boyunca stabil hastalık mevcuttu ve progresyon sonrasında ikinci sıra kemoterapi (paklitaksel) başlandı, ancak hasta tanıdan 15 ay sonra kaybedildi. Kardiyak anjiosarkoma olgularının çoğunda küratif rezeksiyonlar mümkün olmadığından daha ileri tedavi seçeneklerine son derece ihtiyaç vardır. Anahtar Kelimeler: Kardiyak anjiosarkoma, Kemoterapi ABSTRACT Primary cardiac angiosarcoma is a rare disease with poor prognosis. A 34-year-old male patient who underwent an open cardiac surgery and diagnosed as cardiac angiosarcoma on the right atrium was admitted to the medical oncology department. Complete curative resection of the tumor was not possible and postoperatively 6 cycles of combination chemotherapy regimen (ifosphamide with mesna protection and doxorubicin) was given. Patient had stable disease for 8 months, and after progression a second-line chemotherapy (paclitaxel) was started but he died after 15 months of diagnosis. Since curative resections are not possible in most of the cardiac angiosarcoma cases, further treatment options are desperately needed.

show abstract

“…Unfortunately, 66% to 89% of patients have evidence of metastasis at the time of diagnosis (6). In this situation, the prognosis is very poor with median survival of six months (2).…”

Section: Duscussionmentioning

confidence: 99%

“…Therefore, most cases are diagnosed incidentally or too late, subsequently resulting in the poor outcomes (1). Eighty percent of cardiac angiosarcoma present with metastasis with median survival of only six months (2,3). Herein, we describe a case of primary cardiac angiosarcoma with a better survival following surgical resection and radiochemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Three-year survival in primary cardiac angiosarcoma

Fukunaga

Kitai²,

Imai³

et al. 2017

J. Med. Invest.

View full text Add to dashboard Cite

: A healthy 18-year-old girl was referred to our hospital for further evaluations of cardiac angiosarcoma. Transthoracic echocardiography showed an immobile 4.6 cm 3.7 cm cardiac mass. The mass was occupying right atrial chamber and partially, invading into annulus of tricuspid valve on transesophageal echocardiography. At surgery, the mass was seen to be protruding from right atrial appendage and adhering to right side of pericardium. The histological findings were consistent with cardiac angiosarcoma and immunological staining was positive for CD34 and CD31. Afterward, although she received radiochemotherapy, she died of metastasis of cardiac angiosarcoma more than three years after surgical resection.

show abstract

Primary Cardiac Angiosarcoma with Good Response to Paclitaxel

Abstract: Phase III trial comparing vinflunine with docetaxel in second-line advanced non-smallcell lung cancer previously treated with platinum-containing chemotherapy.

Cited by 16 publications

References 5 publications

Favorable Course of Pericardial Angiosarcoma Under Paclitaxel Followed by Pazopanib Treatment Documented by Cardiovascular Magnetic Resonance Imaging

Favorable Course of Pericardial Angiosarcoma Under Paclitaxel Followed by Pazopanib Treatment Documented by Cardiovascular Magnetic Resonance Imaging

Primary Cardiac Angiosarcoma: A Case Report

Three-year survival in primary cardiac angiosarcoma

Contact Info

Product

Resources

About